Back to search
FDAFDA · Food and drugs·Recall number D-0450-2022

Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05

Published February 2, 2022 · Recall initiated: December 29, 2021

Summary

FDA records drug Class II recall D-0450-2022, published February 2, 2022 and initiated December 29, 2021. Recalling firm: Aurobindo Pharma USA Inc.; Status: Terminated; Reported quantity: 792 bottles; Lot: Batch # PF4520028B & PF4520028A, Exp. Date 11/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent and Failed Tablet/Capsule Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if PIOGLITAZONE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
PIOGLITAZONE
Manufacturer
Aurobindo Pharma USA Inc.
Distributor
Nationwide in the US
UPC
0357237221303
Lot
Batch # PF4520028B & PF4520028A, Exp. Date 11/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05 recalled?

Yes. FDA published recall D-0450-2022 on February 2, 2022. Reported hazard: Superpotent and Failed Tablet/Capsule Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: PIOGLITAZONE. UPC: 0357237221303.